About Interius BioTherapeutics
Interius BioTherapeutics is a private company based in Philadelphia, Pennsylvania, incorporated in 2019 in Delaware. It has reported $118,084,524 raised in four offerings on Form D since March 2020. Its chief executive is Philip Johnson, M.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 21, 2024 | Jun 3, 2024 | $51,432,536of $82.5M target | 12 | $4.2M | EquityRule 506(b) | Form D ↗ |
| Oct 5, 2023 | Oct 20, 2023 | $21,451,331fully sold | 13 | $1.6M | DebtRule 506(b) | Form D ↗ |
| May 14, 2021 | May 27, 2021 | $43,625,657of $76.3M target | 25 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Mar 13, 2020 | Mar 27, 2020 | $1,575,000of $3.1M target | 5 | $315K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $118,084,524 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Interius BioTherapeutics's Form D filed Jun 3, 2024.
Earlier filings also listed Philip Johnson (president and ceo, director, last listed Oct 2023), Benjamin Lund (director, last listed Oct 2023), Lori Forrest (executive officer, last listed May 2021), Saar Gill (president, last listed Mar 2020) and Bruce Peacock (secretary and director, last listed Mar 2020).